Strategic US CDMO Industry Trends 2025 analysis and news

April 7, 2026

introduction

The Strategic US CDMO Industry Trends of late 2025 reflect a sector in profound transition, moving beyond simple capacity expansion toward integrated, high-technology partnerships. Within our regular “CDMO Capsules” column, we examine how the last thirty days have seen a surge in domestic infrastructure investment and a shift in ownership structures that will define the market for years to come. US CDMO news shows supply-chain localization accelerating after the Catalent–Novo Holdings deal, driven by geopolitical risk and growing demand for GLP-1, ADC, and cell therapy manufacturing.

The Landscape of American Outsourcing: A Year-End Review

The U.S. pharmaceutical CDMO market is no longer just a support system; it is the engine of drug commercialization. US CDMO market projections show growth from $43.41 billion in 2025 to over $83 billion by 2034, driven by a 7.47% CAGR fueled by onshoring and demand for domestic manufacturing security.

The industry is currently grappling with a “Capacity Gold Rush,” particularly in the sterile fill-finish sector. US CDMO news shows GLP-1 demand locking up major North American capacity, pushing small and mid-cap biotechs toward agile, boutique CDMOs focused on clinical-stage programs.

Strategic Infrastructure and Expansions

In the past month, we have seen the fruition of multi-year investment cycles that emphasize “Specialized Capacity” over “General Capacity.”

Hovione’s New Jersey Hub

Hovione (https://www.hovione.com) announced in late October and into November 2025 the completion of its $100 million investment at its East Windsor, New Jersey site. This expansion specifically doubled its spray drying capacity—a critical technology for improving the bioavailability of complex oral medicines. Spray drying is now a cornerstone for nearly 70% of new molecular entities (NMEs) entering the pipeline that face poor solubility challenges [5.1]. The new 31,000-square-foot building houses two PSD-3 spray dryers, providing a vital North American “supply node” for global partners [5.2].

Fujifilm Diosynth’s North Carolina “Mega-Site”

Meanwhile, Fujifilm Diosynth Biotechnologies (https://fujifilmbiotechnologies.fujifilm.com) celebrated the full operational status of its massive Holly Springs hub. The facility is expected to employ over 1,400 people and focuses on large-scale cell culture and high-speed fill-finish [4.1].

CDMO Capsules: Breaking News and Market Shifts

This month’s “CDMO Capsules” focuses on the high-stakes movements of the industry’s largest players. These updates highlight a market that is consolidating at the top while simultaneously diversifying its technical capabilities.

1. The Novo-Catalent Transformation

The most significant news remains the finalization of Novo Holdings’ acquisition of Catalent (https://www.catalent.com). Now operating under private ownership, Catalent has debuted a new corporate brand focused on “Championing the Missions that Matter” [3.1].

The fallout of this deal is still being measured. The sale of three fill-finish sites to Novo Nordisk has sharply reduced open-market sterile injectable capacity. This has forced competitors—particularly those in the GLP-1 space—to scramble for alternative domestic partners. Industry analysts say the deal marks a shift from service-based CDMOs to captive capacity models backed by Big Pharma ownership.

2. Lonza’s Strategic Pivot

Lonza (https://www.lonza.com) has utilized the year-end to reinforce its U.S. presence, particularly through the integration of the Vacaville, California site acquired earlier this year. Lonza’s Q3 2025 update shows stronger-than-expected demand at its Vacaville site, securing long-term commercial supply deals for large-scale mammalian programs.

Simultaneously, Lonza is preparing for a strategic exit from its Capsules & Health Ingredients (CHI) business. This move allows the company to sharpen its focus on higher-margin, high-growth CDMO services such as biologics, bioconjugates (ADCs), and complex small molecules [6.2].

3. Innovation in Aseptic Filling

Incog BioPharma (https://www.incogbiopharma.com) recently announced a $200 million expansion of its Indiana operations, bringing its total investment in the region to $425 million. This latest phase includes a new 80,000-square-foot building that will eventually house three additional high-speed filling lines [7.1].

Technical Frontiers: Beyond Standard Manufacturing

The Strategic US CDMO Industry Trends are increasingly defined by specialized technological offerings. It is no longer enough to offer stainless steel tanks; CDMOs must now provide proprietary platforms that accelerate the path from DNA to drug product.

The Rise of Radiopharmaceuticals

The U.S. has seen a spike in CDMOs entering the radiopharmaceutical space, a market projected to reach $7.2 billion by 2034 [8.1]. Companies like PharmaLogic (https://www.plogic.com) have recently reported successful dosing in Phase 1/2 studies for novel targeted radiopharmaceuticals. The specialized infrastructure required—including lead-lined facilities and short-lived isotope management—is becoming a new competitive moat for domestic providers [8.2].Nucleus RadioPharma’s appointment of former FDA Commissioner Stephen Hahn as CEO signals rising demand for regulatory expertise in radiopharma CDMO operations.

AI and Digital Tech Transfer

A recurring theme in late 2025 is the integration of Artificial Intelligence. Thermo Fisher Scientific (https://www.thermofisher.com) announced a landmark collaboration with OpenAI to streamline “Accelerator™” drug development. By embedding OpenAI APIs into their PPD clinical research and CDMO workflows, Thermo Fisher aims to significantly reduce the cycle time of tech transfers—the historically slow process of moving a drug from the lab bench to the commercial reactor [9.1, 9.2].

Regulatory and Compliance Watch

Despite the growth, the sector faces intense scrutiny. The FDA issued a series of significant warning letters in late 2025, targeting “Supplier and CMO Oversight Failures” [10.1].

A specific citation toward Catalent’s Indiana facility in late November highlighted CGMP violations related to sterile processing, serving as a reminder that as CDMOs scale at breakneck speeds, quality systems must remain the priority. The FDA’s focus in 2025 has shifted toward Data Integrity and the implementation of electronic quality management systems (eQMS) to ensure that records are contemporaneous and accurate [10.2].

Future Outlook: Heading into 2026

As we close the final “CDMO Capsules” of the year, the trajectory for the U.S. market is clear. We expect to see three dominant themes:

Continued De-risking: More biotechs are moving manufacturing out of Asia and into U.S.-based facilities to avoid potential legislative impacts like the BIOSECURE Act.
Modular Flexibility: A shift away from massive, single-purpose plants toward modular facilities that can be quickly pivoted between different drug modalities (e.g., from peptides to monoclonal antibodies).
Sustainability as a Metric: Following WuXi Biologics’ (https://www.wuxibiologics.com) recent “A” rating from the CDP for climate and water security, ESG metrics are becoming a standard requirement in CDMO RFPs [11].

The U.S. CDMO sector enters 2026 not just as a service provider, but as a critical pillar of national security and medical innovation.

References and Citations

The following references provide the factual basis for this month’s Strategic US CDMO Industry Trends report. These links lead directly to official company newsrooms and industry databases to ensure maximum transparency and technical accuracy.